Moksonidin Belupo (Moxonidine)

Moxonidine, the active ingredient in Moksonidin Belupo, is an imidazoline receptor agonist presented as an oral dosage form for oral use. It is used to lower elevated blood pressure in adults with hypertension. GNH USA supplies Moksonidin Belupo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Moxonidine acts on the central imidazoline I1 receptors to control high blood pressure. It is indicated for several hypertension categories. - Hypertension: reduces elevated systolic and diastolic pressure in adults. - Essential hypertension: provides long‑term control of primary high blood pressure. - Resistant hypertension: may be added when blood pressure remains uncontrolled with other agents.

Moxonidine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dry mouth - Dizziness - Fatigue - Headache

Serious or Rare Side Effects: - Severe hypotension - Bradycardia - Allergic skin reactions such as rash or angioedema

Before prescribing Moksonidin Belupo, clinicians should consider several safety aspects. - Monitor blood pressure: check regularly after initiation and dose adjustments. - Assess renal function: adjust dosing in severe impairment. - Caution in elderly: increased sensitivity to hypotensive effects. - Avoid abrupt discontinuation: taper to prevent rebound hypertension. - Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Moxonidine can interact with other medicines, requiring attention to avoid additive effects.

Major Interactions (Avoid): - Other central antihypertensives (e.g., clonidine): additive hypotension. - Potassium‑sparing diuretics: risk of severe hypotension. - Beta‑blockers: enhanced bradycardia.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive response. - Alcohol: can increase dizziness and hypotension. - CYP2D6 inhibitors: potential increase in plasma concentrations.